Chartwell Investment Partners, LLC Krystal Biotech, Inc. Transaction History

Chartwell Investment Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 03, 2021	SELL	$59.42 - $85.46 $298,169 - $428,838	-5,018 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$40.64 - $61.38 $606,023 - $915,298	-14,912 Reduced 74.82%	5,018 $301,000
Q2 2020 Jul 29, 2020	SELL	$37.03 - $60.0 $217,032 - $351,660	-5,861 Reduced 22.72%	19,930 $826,000
Q1 2020 Apr 30, 2020	BUY	$35.02 - $65.64 $102,643 - $192,390	2,931 Added 12.82%	25,791 $1.12 Million
Q4 2019 Jan 29, 2020	SELL	$33.17 - $65.23 $743,737 - $1.46 Million	-22,422 Reduced 49.52%	22,860 $1.27 Million
Q3 2019 Oct 29, 2019	BUY	$34.72 - $51.3 $1.57 Million - $2.32 Million	45,282 New	45,282 $1.57 Million

302

24.5M

444K

325K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.93B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.